Patient characteristics
| Pt | Sex | Age (y) | Disease duration (y) | STN-DBS duration (m) | UPDRS III off dopa* | UPDRS III DBS on | UPDRS III DBS off | Associated symptoms† | Kinaesthesia results‡ | MMSE | L-dopa equiv dose (mg) | Dopaminergic medication§ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *Assessed preoperatively. | ||||||||||||
| †Dyskinesias (DYS), dystonia (DYSTO), rest tremor (RT). | ||||||||||||
| ‡Correct responses during 2° angular displacement better during ON or OFF stimulation. §100 mg standard levodopa = 125 mg sustained release levodopa, 1.5 mg pramipexole, 6 mg ropinirole, 10 mg bromocriptine, or 1 mg pergolide. | ||||||||||||
| DBS, deep brain stimulation; m, months; MMSE, mini-mental state examination; Pt, patient; y, years. | ||||||||||||
| 1 | M | 44 | 13 | 36 | 62 | 16 | 27 | DYS, RT | ON +25% | 30/30 | 1850 | L-dopa, pergolide |
| 2 | M | 70 | 12 | 12 | 53 | 28 | 32 | ON +13% | 28/30 | 1400 | L-dopa, pramipexole | |
| 3 | F | 68 | 11 | 11 | 22 | 18 | 28 | ON +50% | 28/30 | 900 | L-dopa, pramipexole, selegiline | |
| 4 | M | 56 | 21 | 12 | 48 | 22 | 25 | ON +25% | 28/30 | 1200 | L-dopa, ropinirole, amantadine | |
| 5 | M | 57 | 9 | 12 | 29 | 18 | 27 | +/−0% | 30/30 | 650 | L-dopa, pramipexole | |
| 6 | F | 66 | 22 | 4 | 57 | 46 | 65 | RT | OFF +25% | 29/30 | 1300 | L-dopa, amantadine |
| 7 | F | 71 | 14 | 15 | 70 | 14 | 32 | RT | ON +25% | 30/30 | 2000 | L-dopa, pergolide |
| 8 | F | 51 | 23 | 20 | 70 | 30 | 54 | RT | +/−0% | 29/30 | 617 | L-dopa, amantadine, pramipexole |
| 9 | M | 60 | 10 | 11 | 43 | 35 | 44 | DYS | ON +13% | 29/30 | 367 | L-dopa, ropinirole, amantadine |